AML Characterization by Flow Cytometry Immunophenotyping (Leukemia Diagnostic Panel) in UAE

Clinical Trust & Core Metrics

✓ 99.9% Diagnostic Sensitivity — ISO 9001:2015 accredited processing with advanced 10-color flow cytometry.
✓ Hospital Extraction Only — Sample collection is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety.
✓ Clinical Guidance — Telephonic post-test clinical interpretation support by a DHA-licensed specialist.
✓ Insurance — Direct billing verification via WhatsApp at +971 54 548 8731.

Executive Summary & Core Metrics

This DHA-approved flow cytometry panel delivers same-day, high-resolution immunophenotyping on bone marrow aspirate or peripheral blood, enabling precise AML subtyping and minimal residual disease monitoring. The test uses a 10-color, ≥30-marker panel to classify blast populations, detect aberrant antigen expression, and guide risk-stratified therapy. Results are correlated with morphology, cytogenetics, and clinical presentation to ensure diagnostic accuracy.

Test Overview & Methodology

Flow cytometry immunophenotyping measures surface and cytoplasmic antigens on hematopoietic cells using laser-based multi-parameter detection. Our ISO-accredited protocol employs a comprehensive panel of lineage-defining markers — including CD13, CD33, CD34, CD117, HLA-DR, MPO, CD14, CD64, CD7, CD56, and others — to accurately differentiate AML from other acute leukemias and to identify specific WHO subtypes. The assay achieves high sensitivity for both diagnostic and post-therapy minimal residual disease assessment.

Feature	Our Test (AML Characterization Panel)	Closest Alternative
Precision / Markers	10-color flow cytometry with ≥30 surface and cytoplasmic markers	Standard 4-6 color panel, limited markers
Method	ISO-accredited multi-parameter flow cytometry with cold-chain transport	Routine flow cytometry without cold-chain optimization
Turnaround Time	Same-day report (sample received by 9 AM)	2-3 working days

Physician Insight & Safety Protocols

"As a DHA-registered Specialist Diagnostic Radiologist, I emphasize that no single laboratory result defines a diagnosis. This immunophenotyping panel must be integrated with bone marrow morphology, cytogenetic analysis, and the patient's full clinical context. I urge clinicians and patients to treat these findings as a compass for therapy — not as a standalone verdict — and to maintain transparent dialogue with the treating hematologist."

— Mr. Prabhakar Reddy Kalathoor, Specialist Diagnostic Radiology, DHA Registration ID: 61713011

Critical Advisory — Medication Safety

Do not discontinue or alter any prescribed medication — particularly chemotherapy or targeted agents — without direct consultation with your treating hematologist. Changes in therapy must be guided by a comprehensive clinical review incorporating all laboratory and imaging results.

Exclusion Criteria & Emergency Red Flags

Exclusion for bone marrow aspiration: active skin or soft tissue infection at planned aspiration site, uncorrected severe coagulopathy (INR > 1.8 or platelets < 20,000/µL), or inability to provide informed consent. Minors require legal guardian consent per Federal Decree-Law No. 4 of 2016 on Medical Liability.
Exclusion for blood draw: severe anemia with hemoglobin below 5 g/dL and hemodynamic instability; phlebotomy deferred until stabilized.
Emergency red flags after bone marrow biopsy: rapidly expanding hematoma, persistent fever > 38.5°C, severe pain unresponsive to analgesics, or progressive shortness of breath — seek immediate emergency care.

Patient FAQ & Clinical Guidance

1. What does the AML immunophenotyping panel detect?

Flow cytometry immunophenotyping accurately classifies acute myeloid leukemia by detecting CD13, CD33, CD117, and other lineage-defining antigens. It reveals blast percentage, aberrant marker expression, and helps identify targets for targeted therapy. Results direct risk stratification and monitor minimal residual disease post-remission. The panel is designed to differentiate AML from acute lymphoblastic leukemia and mixed-phenotype acute leukemias.

2. How is the sample collected and what should I expect?

A DHA-certified professional collects 2-3 mL of bone marrow aspirate or 5 mL of peripheral blood using strict cold-chain transport. For bone marrow aspiration, local anesthesia is administered at the posterior iliac crest; the procedure takes 10-15 minutes. Samples are maintained at 18-22°C, never refrigerated or frozen, ensuring cell viability. Same-day reporting is delivered if the sample reaches the lab by 9 AM.

3. Is the test available for home collection and what is the total cost?

Hospital extraction only — the specimen must be collected within an accredited hospital facility; the total package cost is 2,000 AED. The fee covers the hospital-based aspiration procedure, cold-chain transport to our ISO-accredited laboratory, full immunophenotyping analysis, and telephonic post-test clinical guidance. Direct insurance billing can be confirmed via WhatsApp before scheduling. Mobile home phlebotomy is not available for this specimen type due to safety requirements.

UAE Regulatory & Data Privacy Adherence

Regulatory Compliance & Data Protection Framework

Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL): All patient data is processed, stored, and transmitted in full compliance with UAE federal data privacy regulations. Your health information is encrypted and accessed only by authorized medical personnel.
Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields: Our digital health systems adhere to the highest standards for electronic health records, telemedicine guidance, and secure cross-platform data exchange.
Federal Decree-Law No. 4 of 2016 on Medical Liability: All clinical procedures — including bone marrow aspiration and blood draw — are performed under the legal framework governing medical practice, patient consent, and professional accountability in the UAE.
DHA Facility License No. 1143: Our Dubai Healthcare City laboratory operates under direct regulatory oversight by the Dubai Health Authority, ensuring compliance with all local diagnostic standards.

Clinical & Logistical Metadata

Test Name	AML Characterization by Flow Cytometry Immunophenotyping (Leukemia Diagnostic Panel)
Price (AED)	2,000
Turnaround Time	Same-day (sample received by 9 AM)
Sample Type / Matrix	Bone Marrow Aspirate (primary), Peripheral Blood (secondary)
Methodology Used	10-Color Multi-Parameter Flow Cytometry Immunophenotyping
ICD-10-CM Code	C92.00 (Acute myeloblastic leukemia, not having achieved remission)
LOINC Code	48798-3 (Flow cytometry immunophenotyping interpretation for leukemia/lymphoma panel)
DHA Facility License & Address	License No. 1143 \| Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE \| DNA Labs UAE